Emerging evidence demonstrated the role of ADAM17 in cancer progression, invasion and metastasis.27 ADAM17 promoted cell proliferation through accelerating cell cycle from G1 to S phase by increasing CDK2, cyclin E and decreasing p21 and p27 proteins.28 In gastric carcinoma, ADAM17 promoted epithelial‐mesenchymal transition via TGF‐β/Smad pathway.29 These data suggested that ADAM17 may promote cancer progression through affecting cell growth and invasion. The gene discussed is CDK2; the disease is cancer.